Table 1.
Age-standardized prevalence rate of statin use in secondary prevention
| Group | ASPR of statin use in 1999 | Summary | Trend 1 | Trend2 | Trend3 | |||
|---|---|---|---|---|---|---|---|---|
| AAPC | Years | APC | Years | APC | Years | APC | ||
| Total | 8.4% | 12.5 [10.9; 14.1]* | 1999–2005 | 25.4 [21.8; 29.0]* | 2005–2013 | 3.7 [1.7; 5.6]* | ||
| Women | 6.5% | 12.6 [10.9; 14.3]* | 1999–2005 | 25.0 [21.3; 28.8]* | 2005–2013 | 4.1 [2.1; 6.2]* | ||
| 50–59 | 7.6% | 8.3 [5.7; 10.8]* | 1999–2005 | 21.0 [15.5; 26.9]* | 2005–2013 | −0.4 [− 3.4; 2.6] | ||
| 60–69 | 13.6% | 7.3 [5.1; 9.6]* | 1999–2006 | 15.2 [11.4; 19.2]* | 2006–2013 | −0.1 [− 3.4; 3.3] | ||
| 70–79 | 6.6% | 14.0 [12.1; 16.0]* | 1999–2004 | 31.0 [27.7; 34.4]* | 2004–2008 | 11.2 [5.0; 17.8]* | 2008–2013 | 1.3 [− 1.3; 3.9] |
| 80+ | 1.2% | 23.2 [17.3; 29.4]* | 1999–2005 | 40.0 [26.8; 54.5]* | 2005–2013 | 11.9 [5.0; 19.3]* | ||
| Men | 10.0% | 12.3 [10.7; 13.9]* | 1999–2005 | 25.4 [21.8; 29.0]* | 2005–2013 | 3.4 [1.5; 5.3]* | ||
| 50–59 | 18.3% | 6.5 [4.7; 8.4]* | 1999–2005 | 17.2 [13.2; 21.4]* | 2005–2013 | −0.8 [− 3.0; 1.5] | ||
| 60–69 | 12.7% | 10.7 [9.0; 12.4]* | 1999–2005 | 24.9 [21.2; 28.8]* | 2005–2013 | 1.0 [− 0.9; 3.1] | ||
| 70–79 | 7.6% | 15.5 [13.7; 17.4]* | 1999–2005 | 29.2 [25.1; 33.3]* | 2005–2013 | 6.2 [4.1; 8.4]* | ||
| 80+ | 0.8% | 28.0 [22.8; 33.3]* | 1999–2005 | 59.1 [46.5; 72.9]* | 2005–2013 | 8.7 [3.0; 14.6]* | ||
*p < 0.05; ASPR age-standardized prevalence rate, AAPC average annual percentage change, APC annual percentage change